Company (location)

Type of financing

Number of shares, units or warrants (M)

Amount raised (US$M)

Investors; placement agents; details

Date

Total: $770.05M

AB Science SA (Paris)

Private placement

N/A

$11.10

Private placement of new shares with subscription warrants attached generated gross proceeds of approximately €10M (US$11.1M)

8/21/19

Arch Biopartners Inc. (Toronto)

Warrant exercise

0.26W

$0.10

Grossed C$130,000 (US$97,600) from the exercising of 260,000 warrants to buy common shares at C$0.50 per share

8/26/19

Arcturus Therapeutics Holdings Inc. (San Diego)

Registered direct offering

0.94S

$10.90

Registered direct offering of 945,653 shares at $11.50 per share for approx. $10.9M; H.C. Wainwright & Co. as exclusive placement agent

8/5/19

Arcturus Therapeutics Holdings Inc. (San Diego)

Registered direct offering

0.2S

$2.30

Definitive agreement with an institutional investor for the purchase and sale in a registered direct offering of 200,000 shares at a purchase price of $11.50 per share for $2.3M. H.C. Wainwright & Co. as exclusive placement agent for the offering

8/6/19

Bellicum Pharmaceuticals Inc. (Houston)

Private placement

N/A

$82.10

Concurrent private placement of up to $70M of preferred stock and warrants and $12.1M upfront option fee

8/19/19

Biorestorative Therapies Inc. (Melville, N.Y.)

Private placement

5.5S

$5.40

Securities purchase agreement with Arena Investors LP, providing for the issuance and sale to Arena of 5.5M shares of series A preferred stock of the company, a warrant for the purchase of 6M shares of common stock and a convertible promissory note in the principal amount of $500,000 for an aggregate purchase price of $5.4M

8/1/19

Botanix Pharmaceuticals Ltd. (formerly Bone Medical Ltd.), Sydney

Private placement

190.5S

$27.50

Plans to issue approximately 190.5M shares priced at AU$0.21 cents apiece for AU$40M (US$27.5M) in a placement led by U.S.-based biotech investment funds and institutional investors; Cowen and Co. LLC as lead placement agent, with the Australian portion of the placement jointly managed by Argonaut Securities Pty Ltd. and Bell Potter Securities Ltd.

8/2/19

Clovis Oncology Inc. (Boulder, Colo.)

Private placement

N/A

$91.20

Priced $250M aggregate principal amount of its 4.50% convertible senior notes due 2024 in a private placement to qualified institutional buyers and granted to the initial purchasers a 13-day option to purchase up to $37.5M of additional notes; the company has entered aggregate principal amount of its outstanding 2.50% convertible senior notes due 2021, for an aggregate repurchase price of approximately $171.8M; Later that month, Clovis elected to exercise their option to purchase an additional $13M aggregate principal amount of the notes

8/12/19

Devonian Health Group Inc. (Quebec)

Private placement

1.26U

$0.23

Non-brokered private placement of 1.26M units at CA$0.25 each, for aggregate gross proceeds of CA$315,000 (US$236,880)

8/23/19

Emerald Health Therapeutics Inc. (Vancouver, British Columbia)

Convertible Debenture Unit Financing

N/A

$25.00

Binding term sheet with a single Canadian institutional accredited investor for the purchase of 2,500 secured convertible debenture units at $10,000 each for $25M

8/29/19

Essa Pharma Inc. (Vancouver, British Columbia and Houston)

Private placement

18S

$36.00

Canadian and U.S. public offering and private placement to issue up to 18M common shares at $2 each for $36M

8/26/19

Helix Biopharma Corp. (Richmond Hill, Ontario)

Private placement

13.72U

$5.26

Private placement financing of 13.725M units at $0.455 each and the disposition of a 25% stake of its wholly-owned Polish subsidiary, Helix Immuno-Oncology SA, for CA$7M (US$5.26M)

8/23/19

Hemostemix Inc. (Calgary, Alberta)

Loan agreement

N/A

$0.50

Loan agreement with J.M. Wood Investments Ltd. (JMWI) for a secured loan in an aggregate principal amount of up to $2M; minimum amount of $500,000 received

8/2/19

Ico Therapeutics Inc. (Vancouver, British Columbia)

Private placement

41.2U

$1.50

Nonbrokered private placement issued 41.2M units at a price of CA5 cents for CA$2M (US$1.5M)

8/20/19

Inovio Pharmaceuticals Inc. (Plymouth Meeting, Pa.)

Private placement

N/A

$15.00

Private placement of convertible bonds with an aggregate principal amount of KRW18B (US$15M) issued to institutional investors led by Korea Investment Partners

8/8/19

Ironwood Pharmaceuticals Inc. (Cambridge, Mass.)

Convertible senior notes offering

N/A

$390.00

Offering $175M aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2024, and $175M aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2026; exercised option to purchase, within a 13-day period, up to an additional $25M aggregate principal amount of the 2024 notes and $25M aggregate principal amount of the 2026 notes

8/9/19

Noxxon Pharma NV (Berlin)

Private placement

N/A

$1.10

Letters of intent and binding commitments for long-term investment of €1M (US$1.1M) through a private placement plus additional commitment for a future private placement

8/7/19

Obseva SA (Geneva)

Credit facility

N/A

$25.00

$75M senior secured credit facility with Oxford Finance LLC in three tranches, with the initial $25M available upon closing

8/8/19

Orphazyme A/S (Copenhagen)

Debt facility

N/A

$9.97

Structured debt facility (Loan Agreement) with Kreos Capital VI (UK) Ltd. to secure funding of €9M (US$9.97M)

8/29/19

Seelos Therapeutics Inc. (New York)

Registered direct offering

4.475S

$6.70

Securities purchase agreement with certain institutional investors for the purchase and sale of 4.475M shares of common stock at $1.50 each for approx. $6.7M in a registered direct offering

8/26/19

Seelos Therapeutics Inc. (New York)

Private placement

W for 2.23S

N/A

Unregistered warrants to purchase up to 2.23M shares of common stock at $1.78 per share in a concurrent private placement

8/26/19

Sernova Corp. (London, Ontario)

Private placement

Units

$2.33

Completed a first closing of $2,333,500 of its non-brokered private placement

8/19/19

Sophiris Bio Inc. (San Diego)

Registered direct offering

5.33S

$4.00

Registered direct offering for the sale 5.33M of its common shares (or pre-funded warrants to purchase common shares) at $0.75 each, for approx. $4M

8/28/19

Sophiris Bio Inc. (San Diego)

Private placement

W for 5.33S

N/A

Warrants to purchase up to 5.33M common shares with an exercise price of $0.95 each and a five-year exercise period starting 6 months from the issuance date in a private placement

8/28/19

Titan Pharmaceuticals Inc. (South San Francisco)

Registered direct offering

2.85S

$2.10

Securities purchase agreement to sell 2.85M shares (or prefunded warrants to purchase common stock) to a single accredited institutional investor for approximately $2.1M in a registered direct offering

8/8/19

Titan Pharmaceuticals Inc. (South San Francisco)

Private placement

W for 2.85S

N/A

Warrants to purchase up to an aggregate of 2,852,314 shares of common stock at an exercisable price of $1.07 per share in a private placement

8/8/19

Vaccinex Inc. (Rochester, N.Y.)

Private placement

3.38S

$13.80

Stock purchase agreement with a syndicate of new and existing investors for a private placement of 3.38M shares at $4.08 each for aggregate gross proceeds of approximately $13.8M

8/1/19

Veloxis Pharmaceuticals A/S (Copenhagen)

Warrant exercise

6.48S

$0.96

Warrant exercise of 6.48M new shares with a nominal value of DKK 0.10 each corresponding to DKK 648,606 (US$96,700) by current and former employees

8/27/19


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.

 

No Comments